Claims for Patent: 7,037,647

Summary for Patent: 7,037,647

Title:	Prostate-specific membrane antigen and uses thereof
Abstract:	This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM\') antigen. This invention provides an isolated nucleic acid molecule encoding a prostate-specific membrane antigen promoter. This invention provides a method of detecting hematogenous micrometastic tumor cells of a subject, and determining prostate cancer progression in a subject.
Inventor(s):	Israeli; Ron S. (Staten Island, NY), Heston; Warren D. W. (New York, NY), Fair; William R. (New York, NY)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:	08/894,583
Patent Claims:	1. A method of detecting expression of an alternatively spliced prostate specific membrane antigen in a cell or tissue, which alternatively spliced prostate specific membrane antigen consists essentially of consecutive amino acids, the amino acid sequence of which is set forth in SEQ ID NO:128 beginning with methionine at position number 58 and ending with alanine at position number 750, the nucleic acid encoding the alternatively spliced prostate specific membrane antigen having an intron splice site located between the G and T nucleotides at positions 114 and 115, respectively, as set forth in SEQ ID NO:1, wherein a splice at said site results in formation of an exon-exon junction characteristic of said alternatively spliced prostate specific membrane antigen, said method comprising: (1) contacting mRNA obtained from the cell or tissue with a detectable nucleic acid of at least 15 nucleotides in length which specifically hybridizes across said exon-exon junction; and (2) determining whether the detectable nucleic acid hybridizes to the mRNA, wherein the presence of the detectable nucleic acid hybridized to the mRNA indicates expression of alternatively spliced prostate specific membrane antigen in the cell or tissue. 2. The method of claim 1, wherein the detectable nucleic acid is labeled with a detectable label. 3. The method of claim 2, wherein the detectable label is a radioisotope or fluorescent dye.

Details for Patent 7,037,647

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-02-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-02-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-02-24